Wall Street analysts forecast that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will report earnings of ($0.19) per share for the current quarter, Zacks reports. Three analysts have made estimates for Oramed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.17). Oramed Pharmaceuticals posted earnings per share of ($0.18) in the same quarter last year, which would indicate a negative year over year growth rate of 5.6%. The company is scheduled to report its next quarterly earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year earnings of ($0.99) per share for the current financial year, with EPS estimates ranging from ($1.05) to ($0.92). For the next financial year, analysts forecast that the company will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.00) to ($0.98). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Oramed Pharmaceuticals.
Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Wednesday, November 28th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.10. Oramed Pharmaceuticals had a negative return on equity of 59.72% and a negative net margin of 577.99%. The firm had revenue of $0.62 million for the quarter.
Separately, HC Wainwright set a $25.00 price objective on Oramed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 12th.
A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. BlackRock Inc. increased its position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 69,343 shares of the biotechnology company’s stock after buying an additional 40,114 shares during the period. BlackRock Inc. owned 0.40% of Oramed Pharmaceuticals worth $208,000 at the end of the most recent reporting period. 9.97% of the stock is owned by institutional investors and hedge funds.
NASDAQ:ORMP traded up $0.03 during mid-day trading on Monday, reaching $3.29. The stock had a trading volume of 18,992 shares, compared to its average volume of 57,935. Oramed Pharmaceuticals has a fifty-two week low of $2.78 and a fifty-two week high of $8.59.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.